Cargando…

Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System

To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT1...

Descripción completa

Detalles Bibliográficos
Autores principales: Amodio, Emanuele, Minutolo, Giuseppa, Casuccio, Alessandra, Costantino, Claudio, Graziano, Giorgio, Mazzucco, Walter, Pieri, Alessia, Vitale, Francesco, Zarcone, Maurizio, Restivo, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954936/
https://www.ncbi.nlm.nih.gov/pubmed/35334977
http://dx.doi.org/10.3390/vaccines10030345
_version_ 1784676215868620800
author Amodio, Emanuele
Minutolo, Giuseppa
Casuccio, Alessandra
Costantino, Claudio
Graziano, Giorgio
Mazzucco, Walter
Pieri, Alessia
Vitale, Francesco
Zarcone, Maurizio
Restivo, Vincenzo
author_facet Amodio, Emanuele
Minutolo, Giuseppa
Casuccio, Alessandra
Costantino, Claudio
Graziano, Giorgio
Mazzucco, Walter
Pieri, Alessia
Vitale, Francesco
Zarcone, Maurizio
Restivo, Vincenzo
author_sort Amodio, Emanuele
collection PubMed
description To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT162b2 (Comirnaty, Pfizer-BioNTech) was the first and only authorized vaccine in Italy for selected categories, such as healthcare workers, fragile patients and people aged over 80 years old. To master our knowledge about BNT162b2 adverse reactions (ARs), an active surveillance system based on instant messaging was realized for voluntary participants who had been vaccinated at COVID-19 Vaccination Center of the Palermo University Hospital. Overall, 293 vaccinated persons were included in this study, which were more frequently healthcare workers (n = 207, 70.6% with a median age of 36 years, IQR = 29–55) followed by health professional students (n = 31, 10.6% with a median age of 27 years, IQR = 25–29), reporting 82.6% of at least one local or systemic AR. In details, the frequency of at least one local or systemic AR after the second dose of Comirnaty (n = 235, 80.2%) was statistically significant with higher value in comparison to the first one (n = 149, 50.9%; p < 0.001). However, local pain, swelling, joint pain and muscular pain after the second dose were the symptom causing a statistically significant working limitation. The youngest persons showed a higher risk to have either local or systemic ARs (aOR = 7.5, CI 95% = 2.9–18.9), while females had a higher risk of having systemic ARs (aOR = 1.8, CI 95% = 1.1–3.0). Despite the small sample examined, this active surveillance system by instant messaging seems to detect a higher ARs prevalence with respect to data obtained by the passive surveillance. Further studies could be required in order to optimize this clinical monitoring that could be considered an efficient and timely active surveillance.
format Online
Article
Text
id pubmed-8954936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89549362022-03-26 Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System Amodio, Emanuele Minutolo, Giuseppa Casuccio, Alessandra Costantino, Claudio Graziano, Giorgio Mazzucco, Walter Pieri, Alessia Vitale, Francesco Zarcone, Maurizio Restivo, Vincenzo Vaccines (Basel) Article To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT162b2 (Comirnaty, Pfizer-BioNTech) was the first and only authorized vaccine in Italy for selected categories, such as healthcare workers, fragile patients and people aged over 80 years old. To master our knowledge about BNT162b2 adverse reactions (ARs), an active surveillance system based on instant messaging was realized for voluntary participants who had been vaccinated at COVID-19 Vaccination Center of the Palermo University Hospital. Overall, 293 vaccinated persons were included in this study, which were more frequently healthcare workers (n = 207, 70.6% with a median age of 36 years, IQR = 29–55) followed by health professional students (n = 31, 10.6% with a median age of 27 years, IQR = 25–29), reporting 82.6% of at least one local or systemic AR. In details, the frequency of at least one local or systemic AR after the second dose of Comirnaty (n = 235, 80.2%) was statistically significant with higher value in comparison to the first one (n = 149, 50.9%; p < 0.001). However, local pain, swelling, joint pain and muscular pain after the second dose were the symptom causing a statistically significant working limitation. The youngest persons showed a higher risk to have either local or systemic ARs (aOR = 7.5, CI 95% = 2.9–18.9), while females had a higher risk of having systemic ARs (aOR = 1.8, CI 95% = 1.1–3.0). Despite the small sample examined, this active surveillance system by instant messaging seems to detect a higher ARs prevalence with respect to data obtained by the passive surveillance. Further studies could be required in order to optimize this clinical monitoring that could be considered an efficient and timely active surveillance. MDPI 2022-02-23 /pmc/articles/PMC8954936/ /pubmed/35334977 http://dx.doi.org/10.3390/vaccines10030345 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Amodio, Emanuele
Minutolo, Giuseppa
Casuccio, Alessandra
Costantino, Claudio
Graziano, Giorgio
Mazzucco, Walter
Pieri, Alessia
Vitale, Francesco
Zarcone, Maurizio
Restivo, Vincenzo
Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System
title Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System
title_full Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System
title_fullStr Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System
title_full_unstemmed Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System
title_short Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System
title_sort adverse reactions to anti-sars-cov-2 vaccine: a prospective cohort study based on an active surveillance system
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954936/
https://www.ncbi.nlm.nih.gov/pubmed/35334977
http://dx.doi.org/10.3390/vaccines10030345
work_keys_str_mv AT amodioemanuele adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT minutologiuseppa adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT casuccioalessandra adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT costantinoclaudio adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT grazianogiorgio adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT mazzuccowalter adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT pierialessia adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT vitalefrancesco adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT zarconemaurizio adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem
AT restivovincenzo adversereactionstoantisarscov2vaccineaprospectivecohortstudybasedonanactivesurveillancesystem